BioCentury | Mar 9, 2021
Product Development

AnaptysBio looks ahead to other indications after Phase II miss in palmoplantar pustulosis

Following a Phase II miss for imsidolimab to treat palmoplantar pustulosis, AnaptysBio will look ahead to five other indications for the IL-36R antagonist. The company plans to bring imsidolimab (ANB019) into Phase III testing mid-year for generalized...
BioCentury | Mar 9, 2021
Product Development

Palmoplantar pustulosis pipeline: Data Byte

AnaptysBio’s Phase II miss for palmoplantar pustulosis (PPP) may indicate that overactive IL-36 signaling is not the dominant driver of the disease. The news could be a warning for Boehringer Ingelheim GmbH, which has spesolimab (BI...
BioCentury | Jan 8, 2021
Emerging Company Profile

Co-founded by Mukherjee and Vale, Myeloid is directing monocytes against cancer

Myeloid is engineering monocytes as cellular cancer therapies by programming pluripotent myeloid cells to target tumor cells and conduct a suite of myeloid antitumor functions. Ronald Vale and Siddhartha Mukherjee are among the founders of...
BioCentury | Oct 16, 2020
Product Development

Recent Phase III disappointment aside, the heart failure pipeline holds plenty to look forward to

The most recent Phase III data from a heart failure candidate may have been underwhelming, but a look at the broader pipeline suggests the long period of drought in innovation could soon give way to...
BioCentury | Oct 13, 2020

Oct. 13 Quick Takes: Sovereign wealth fund backs Evotec; plus Canaan, EdiGene, Cedilla, Rappta and Lassogen

UAE fund, Novo invest €250M in EvotecEvotec SE (Xetra:EVT) raised €250 million ($295.5 million) via a private placement in which it sold shares to Mubadala Investment Co. and Novo Holdings A/S. Mubadala, a United Arab Emirates...
BioCentury | Aug 27, 2020
Distillery Therapeutics

Targeting the PP2A-STRN3 interaction to treat gastric cancer

DISEASE CATEGORY: Cancer INDICATION: Gastric cancer Interrupting the interaction between PP2A catalytic subunit PPP2CA and STRN3, a regulatory subunit, could treat gastric cancer. In patients, STRN3 expression...
BioCentury | Jun 5, 2020
Product Development

Emergent playing key role in manufacturing COVID-19 vaccines via PPP set up for flu

If and when Americans are vaccinated against COVID-19, they might take a moment to thank another virus, H1N1 influenza. The country’s poor response to an H1N1 outbreak in 2009, including vaccine delays and shortages caused...
BioCentury | May 8, 2020
Politics, Policy & Law

Partnership offers hope for COVID drug development

As the world eyes a return to post-COVID crisis “normalcy,” a robust global recovery will depend on effective treatments and ultimately a vaccine. Yes, more than 400 research and clinical programs are already under way,...
BioCentury | Apr 7, 2020
Politics & Policy

Path emerges for VC-backed biotechs to access paycheck protection loans

Lawyers have identified workarounds that allow venture-backed biotechs to comply with Small Business Administration affiliation rules to access an emergency forgivable loan program for small businesses created by the Coronavirus Aid, Relief, and Economic Security...
BioCentury | Apr 2, 2020
Politics, Policy & Law

VC-backed biotechs may be excluded from coronavirus loan program

Venture-backed companies may be shut out of an emergency forgivable loan program for small businesses created by the Coronavirus Aid, Relief, and Economic Security (CARES) Act unless the Trump administration takes urgent action to modify...
Items per page:
1 - 10 of 370